Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk index stratifies pediatric leukemia patients undergoing HSCT

Key clinical point: A validated disease risk index was developed for pediatric patients with acute myeloid or lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Major finding: For pediatric patients with very-high-risk acute myeloid leukemia, the 5-year probability of leukemia-free survival was 21%.

Study details: A risk modeling study involving 1,135 children with acute myeloid leukemia and 1,228 with acute lymphoblastic leukemia.

Disclosures: The study was funded by the National Institutes of Health. The investigators disclosed no conflicts of interest.


Qayed M et al. ASCO 2020, Abstract 7503.